Ratings by Cantor Fitzgerald (Josh Schimmer)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/27/2026 | Invivyd Inc. | IVVD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/25/2026 | Apnimed Inc. | APMD | New Coverage | Overweight (N/A) |
25.63 (26.85) |
4.76% | Details | |
| 8/11/2026 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2026 | Trevi Therapeutics | TRVI | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/31/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/7/2026 | Crinetics | CRNX | Downgrade | Neutral (Overweight) |
42.23 (84.95) |
101.16% | Details | |
| 6/25/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/29/2026 | ARS Pharmaceuticals Inc | SPRY | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/26/2026 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/15/2026 | GH Research PLC | GHRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/8/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2026 | Mirum Pharmaceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2026 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/18/2026 | Trevi Therapeutics | TRVI | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/11/2026 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2026 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/10/2026 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Nuvalent | NUVL | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/27/2026 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/22/2026 | DiaMedica Therapeutics Inc. | DMAC | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/16/2026 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/9/2026 | Krystal Biotech | KRYS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/8/2026 | Compass Pathways | CMPS | Maintain | Overweight (Overweight) |
|
Details | ||
| 1/5/2026 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/31/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Overweight (N/A) |
|
Details | ||
| 12/2/2025 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/21/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Trevi Therapeutics | TRVI | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/14/2025 | DiaMedica Therapeutics Inc. | DMAC | New Coverage | Overweight (N/A) |
5.42 (6.45) |
19% | Details | |
| 11/11/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/5/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 11/4/2025 | Xenon Pharmaceuticals | XENE | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/30/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/17/2025 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/10/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 10/6/2025 | Invivyd Inc. | IVVD | New Coverage | Overweight (N/A) |
1.16 (0.88) |
-24.14% | Details | |
| 9/26/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/24/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/23/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/22/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/10/2025 | GH Research PLC | GHRS | Maintain | Overweight (Overweight) |
|
Details | ||
| 9/8/2025 | Denali Therapeutics Inc. | DNLI | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/21/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/14/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 8/7/2025 | Mirum Pharmaceuticals | MIRM | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/29/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/25/2025 | Krystal Biotech | KRYS | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/25/2025 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/23/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/3/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 7/1/2025 | Trevi Therapeutics | TRVI | New Coverage | Overweight (N/A) |
5.47 (16.57) |
202.93% | Details | |
| 6/13/2025 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (Overweight) |
|
Details | ||
| 6/4/2025 | GH Research PLC | GHRS | New Coverage | Overweight (N/A) |
12.08 (27.36) |
126.49% | Details | |
| 5/16/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/16/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 5/6/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/28/2025 | CG Oncology | CGON | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/23/2025 | Tourmaline Bio | TRML | Maintain | Overweight (Overweight) |
|
Details | ||
| 4/10/2025 | Denali Therapeutics Inc. | DNLI | Upgrade | Overweight (Neutral) |
12.86 (23.27) |
80.95% | Details | |
| 4/1/2025 | Aardvark Therapeutics Inc | AARD | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/25/2025 | Artiva Biotherapeutics | ARTV | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/24/2025 | Rocket Pharmaceuticals | RCKT | Maintain | Overweight (Overweight) |
|
Details | ||
| 3/20/2025 | ARS Pharmaceuticals Inc | SPRY | Maintain | Overweight (N/A) |
|
Details | ||
| 3/10/2025 | Aardvark Therapeutics Inc | AARD | New Coverage | Overweight (N/A) |
10.13 (5.92) |
-41.56% | Details | |
| 3/6/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Crinetics | CRNX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Janux Therapeutics | JANX | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/28/2025 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2025 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 2/11/2025 | Septerna Inc | SEPN | Maintain | Overweight (Overweight) |
|
Details | ||
| 2/7/2025 | Neurocrine Bio. | NBIX | Maintain | Overweight (Overweight) |
|
Details | ||
| 12/3/2024 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 11/19/2024 | Septerna Inc | SEPN | New Coverage | Overweight (N/A) |
23.55 (37.68) |
60% | Details | |
| 10/14/2024 | Longboard Pharmaceuticals Inc | LBPH | Downgrade | Neutral (Overweight) |
38.90 (59.98) |
54.19% | Details | |
| 10/7/2024 | Denali Therapeutics Inc. | DNLI | Downgrade | Neutral (Overweight) |
28.63 (23.27) |
-18.72% | Details | |
| 8/19/2024 | ARS Pharmaceuticals Inc | SPRY | New Coverage | Overweight (N/A) |
13.33 (5.77) |
-56.71% | Details | |
| 8/13/2024 | Artiva Biotherapeutics | ARTV | New Coverage | Overweight (N/A) |
11.22 (11.28) |
0.53% | Details | |
| 7/1/2024 | Longboard Pharmaceuticals Inc | LBPH | Maintain | Overweight (N/A) |
|
Details | ||
| 6/12/2024 | Zura Bio Ltd. | ZURA | New Coverage | Overweight (N/A) |
3.83 (5.65) |
47.52% | Details | |
| 3/20/2024 | Janux Therapeutics | JANX | New Coverage | Overweight (N/A) |
38.81 (18.89) |
-51.33% | Details | |
| 3/11/2024 | BridgeBio Pharma | BBIO | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | Crinetics | CRNX | Maintain | Overweight (N/A) |
|
Details | ||
| 3/4/2024 | Mirum Pharamceuticals | MIRM | Maintain | Overweight (N/A) |
|
Details | ||
| 2/20/2024 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
47.93 (75.86) |
58.27% | Details | |
| 11/15/2023 | Cabaletta Bio Inc. | CABA | Maintain | Overweight (N/A) |
|
Details | ||
| 10/24/2023 | Neurocrine Bio. | NBIX | New Coverage | Overweight (N/A) |
107.91 (156.76) |
45.27% | Details | |
| 10/24/2023 | Crinetics | CRNX | New Coverage | Overweight (N/A) |
28.26 (42.23) |
49.43% | Details | |
| 10/24/2023 | Denali Therapeutics Inc. | DNLI | New Coverage | Overweight (N/A) |
18.70 (23.27) |
24.44% | Details | |
| 10/24/2023 | Krystal Biotech | KRYS | New Coverage | Overweight (N/A) |
108.96 (363.84) |
233.92% | Details |
